Logo

Symptomatic WM

It’s important to consider the available WM therapy options, as the right one will be determined by individual patient factors.

The choice of therapy for your patient should be guided by disease presentation and patient-related factors including age, comorbidities and complications requiring immediate treatment response.[1] The ESMO 2018 and the IWWM 2020 guidelines outline first-line treatment options for patients with symptomatic WM.[1][2]

These should be used in conjunction with local policy and drug licenses when developing treatment plans.

To access the latest data for WM therapies, click the link below. The information on this website is limited to healthcare professionals. You will be required to create, or log in to your local Janssen Medical Cloud account.

Log in to discover the latest therapy options for WM
Expert opinions on disease management and clinical practice

ESMO=European Society for Medical Oncology; WM= Waldenström’s macroglobulinemia.

This site has been developed by Janssen-Cilag International NV. Janssen-Cilag International NV is the responsible editor of this document.

ITEM CODE: CP-237931 | DATE OF PREPARATION: June 2021

References

Kastritis E, et al. Waldenström’s macroglobulinemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv41–iv50.
Castillo JJ, et al. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. Lancet Haematol. 2020;7(11):e827–e837.